Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Curr Opin Otolaryngol Head Neck Surg. 2022 Apr 1;30(2):87-93. doi: 10.1097/MOO.0000000000000792.
The aim of this review is to discuss recent studies on the assessment of sarcopenia and its predictive and prognostic value in head and neck cancer (HNC) patients.
There is increasing evidence that low skeletal muscle mass (SMM), often named sarcopenia, can easily be assessed on cross-sectional imaging of the head and neck and is associated with chemotherapy (dose limiting) and radiotherapy toxicity and survival.
SMM measurement at the level of the third cervical vertebra (C3) on routine computed tomography and magnetic resonance imaging is easy and robust to perform. Several studies have shown a significantly higher incidence of cisplatin dose limiting toxicity in HNC patients with a low SMM. In HNC patients pretreatment low SMM is associated with acute and late toxicity and adverse events of radiotherapy, complications of major head and neck surgery and decreased disease-specific and overall survival. This information can be used for individualized treatment planning in HNC patients with low SMM.
本文旨在讨论最近关于肌少症评估及其对头颈癌（HNC）患者的预测和预后价值的研究。
越来越多的证据表明，低骨骼肌量（SMM），通常称为肌少症，可通过头颈部的横断面成像轻松评估，并且与化疗（剂量限制）和放疗毒性及生存相关。
在常规计算机断层扫描和磁共振成像上测量第三颈椎（C3）水平的 SMM 既简单又可靠。多项研究表明，SMM 低的 HNC 患者发生顺铂剂量限制毒性的发生率显著更高。在 HNC 患者中，治疗前 SMM 低与放疗的急性和晚期毒性及不良事件、头颈部大手术的并发症以及疾病特异性和总体生存率降低相关。这些信息可用于 SMM 低的 HNC 患者的个体化治疗计划。
